Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Crinetics Pharmaceuticals ( (CRNX) ).
On September 25, 2025, Crinetics Pharmaceuticals announced that the FDA approved PALSONIFYTM (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. PALSONIFY, a once-daily oral therapy, marks a significant advancement in acromegaly treatment, offering a non-invasive alternative to traditional injections. The approval is based on successful Phase 3 trials demonstrating the drug’s efficacy and safety, and it represents a pivotal milestone for Crinetics as it enhances its position as a leader in endocrine-focused pharmaceuticals. The company is also working to ensure broad access to PALSONIFY and has launched a support program, CrinetiCARE, to assist patients throughout their treatment journey.
The most recent analyst rating on (CRNX) stock is a Buy with a $143.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.
Spark’s Take on CRNX Stock
According to Spark, TipRanks’ AI Analyst, CRNX is a Neutral.
Crinetics Pharmaceuticals’ overall stock score is primarily influenced by its financial challenges, including persistent losses and cash flow issues. While technical indicators are neutral, the valuation is negatively impacted by ongoing losses. Positive developments from the earnings call and corporate events provide some optimism, but the financial instability remains a significant concern.
To see Spark’s full report on CRNX stock, click here.
More about Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and endocrine-related tumors. The company is committed to developing science-based solutions that address patient needs.
Average Trading Volume: 1,073,942
Technical Sentiment Signal: Buy
Current Market Cap: $3.31B
For a thorough assessment of CRNX stock, go to TipRanks’ Stock Analysis page.